E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
May 24, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Upcoming Investor Conferences
May 18, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Record First Quarter 2022 Financial Results
May 05, 2022 16:00 ET | electroCore, Inc.
First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast today, May 5, 2022 at, 4:30 PM EDT ...
ODYY-Main.png
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
May 05, 2022 08:30 ET | Odyssey Group Intl Inc.
Irvine, CA, May 05, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products,...
True Lacrosse Advances Player Safety With HEADCHECK HEALTH Partnership
May 03, 2022 09:00 ET | HeadCheck Health, Inc.
CHICAGO, May 03, 2022 (GLOBE NEWSWIRE) -- True Lacrosse, LLC. ("True Lacrosse"), and HEADCHECK HEALTH, Inc. ("HEADCHECK"), a leading tech-enabled provider of concussion protocol management for...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce First Quarter 2022 Financial Results on May 5
April 28, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Completes Sale of New Jersey Tax Benefits
April 26, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology
April 21, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published...
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
April 20, 2022 08:30 ET | Odyssey Group Intl Inc.
Irvine, CA, April 20, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program
April 19, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for...